Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDH305 in IDH1 Mutant Grade II or III Glioma
NCT02977689Phase 2Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Apr 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idh305 in glioma, sponsored by NYU Langone Health. Primary endpoint: Radiographic response rate at 8 weeks. Planned start Apr 2018; status: withdrawn.
02
Drugs
idh305
03
Conditions
glioma
Beyond the preview
Go deeper on NCT02977689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02977689.